A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
Clinical trial NCT07260513 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07260513
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-27
- Primary completion
- 2028-12-31
- Enrollment
- 126
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.